Patents Examined by Janet L Coppins
  • Patent number: 11911610
    Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: February 27, 2024
    Assignee: Novocure GmbH
    Inventors: David Tran, Son Bang Le, Dongjiang Chen
  • Patent number: 11896565
    Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, one or more ketone precursors, supplements, or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: February 13, 2024
    Inventor: Gary Millet
  • Patent number: 11890270
    Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: February 6, 2024
    Assignee: Siga Technologies, Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. S. Anderson, William C. Weimers, Dylan Nelson, Tove' C. Bolken, Dennis E. Hruby, Michael H. O'Neill, Gary Sweetapple, Kelley A. McCloughan
  • Patent number: 11865113
    Abstract: Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: January 9, 2024
    Inventors: Nigel R. A. Beeley, J. Gordon Foulkes, Kieran George Mooney, Charles Rodney Greenaway Evans, Keith Arthur Johnson, Howard G. Welgus, Celia P. Jenkinson
  • Patent number: 11865118
    Abstract: The present invention relates to compounds of formula (I) and their use for treating or preventing a bacterial infection or as an antibacterial agent and/or as a ?-lactamase inhibitor.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: January 9, 2024
    Assignee: MUTABILIS
    Inventors: Julien Barbion, Audrey Caravano, Sophie Chasset, Francis Chevreuil, Frédéric Le Strat, Christophe Simon, Julie Brias, Rémi Lebel
  • Patent number: 11826315
    Abstract: Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: November 28, 2023
    Assignees: Tvardi Therapeutics, Baylor College of Medicine
    Inventors: Sofia De Achaval, David John Tweardy
  • Patent number: 11813233
    Abstract: A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and choline. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-? phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human. The composition can be administered to the individual in a daily dose that provides 5.5 mg/day to 5,500 mg/day of the choline, for example 85 mg/day to 3,500 mg/day of the choline.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 14, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Claus Rieker, Julie Hudry-Labbe, Jeroen Antonius Johannes Schmitt, Corina Boschat, Yvonne Beata Silber
  • Patent number: 11806332
    Abstract: The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (MPro) in a patient. The disclosure also provides other methods as well as pharmaceutical formulations for use in treating COVID-19 patients.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: November 7, 2023
    Inventors: Wenshe Liu, Kai Yang, Erol Vatansever, Shiqing Xu
  • Patent number: 11793797
    Abstract: Described herein is the use of a LOXL2 inhibitor in the treatment or prevention of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 24, 2023
    Assignee: PHARMAKEA, INC.
    Inventors: Gretchen Bain, Jillian Frances Evans, Deidre A. Mackenna, John Howard Hutchinson
  • Patent number: 11771705
    Abstract: The present invention relates to the field of prostate cancer treatment, and in particular the field of prostate cancer treatment by Androgen Deprivation Therapy (ADT). The present treatment involves oral administration of an estetrol component in conjunction with ADT.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: October 3, 2023
    Assignee: FUND SA
    Inventor: F. M. J. Debruyne
  • Patent number: 11759464
    Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: September 19, 2023
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Ernest Loumaye, Jean-Pierre Gotteland, Oliver Pohl
  • Patent number: 11752120
    Abstract: The present invention belongs to the technical field of medicine, and specifically relates to use of succinic acid in increasing sensitivity of bacteria to antibiotics. The present invention found that the succinic acid can increase proton motive force of bacteria, thereby increasing the number of antibiotics entering the bacteria, and eventually killing the bacteria. Therefore, the succinic acid can increase the sensitivity of bacteria to antibiotics, thereby overcoming the problem of bacterial drug resistance. Combining succinic acid with antibiotics can significantly improve the bactericidal effect of the antibiotics, which has better effects and higher safety and operability compared with only using antibiotics as antibacterial drugs at present.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: September 12, 2023
    Inventors: Hui Li, Bo Peng, Xuanxian Peng
  • Patent number: 11723861
    Abstract: The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 ?g.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 15, 2023
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Frank Löscher, Kirsten Eickhoff
  • Patent number: 11707447
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: July 25, 2023
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Patent number: 11696897
    Abstract: A method for a treatment of individuals suffering from diseases associated with sulfatase deficiencies including lysosomal storage disease includes administering at least once a therapeutically effective amount of at least one retinoid. In particular, the compounds tazaroten and bexaroten have beneficial effects on these individuals. Pharmaceutical compositions comprising both active agents namely, tazaroten and bexaroten compounds, or similar compounds, provides for ready treatment of such individuals, and enhanced treatment is achieved with at least two active agents.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: July 11, 2023
    Inventors: Lars Schlotawa, Matthias Kettwig, Karthikeyan Radhakrishnan, Thomas Dierks, Jutta Gartner, Matthias Baud
  • Patent number: 11672800
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 13, 2023
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre
  • Patent number: 11666555
    Abstract: Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 6, 2023
    Inventors: Hai-Feng Ji, Garth David Ehrlich, Donald Carl Hall, Jr., Jaroslaw E. Krol, John P. Cahill
  • Patent number: 11628199
    Abstract: A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 18, 2023
    Inventors: Jie Zhang, Wang Huang, Huarong Yang
  • Patent number: 11596617
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: March 7, 2023
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11591363
    Abstract: The present invention relates to a cocrystal of beta-sitosterol or a pharmaceutically acceptable ester thereof or an edible acceptable ester thereof and an organic carboxylic acid coformer, an hydrate crystal form of beta-sitosterol having 1.25 molecules of water per molecule of beta-sitosterol and a combination that comprises a cocrystal of beta-sitosterol and an organic carboxylic acid; and the hydrate crystal form of beta-sitosterol having 1.25 molecules of water per molecule of beta-sitosterol. It also relates to processes for their preparation, and compositions containing them, as well as their use as a medicament or dietary supplement or functional food, and in particular in the prophylaxis and/or treatment of a disease or conditions that involves an alteration of lipid metabolism, circulating levels of lipids in the blood and/or lipid composition in tissues and organs.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 28, 2023
    Inventors: Rafel Prohens López, Rafael Barbas Cañero, Anna Portell Bueso, Mariona Palou March, Francisca Serra Vich, Andreu Palou March